R-CHOP shine sunan da aka rage don haɗuwa da kwayoyi da aka saba amfani da su kamar yadda ake amfani da su don maganin cututtuka, kamar su lymphomas wadanda ba Hodgkin, ko NHLs . Kowace wasika a R-CHOP tana nufin wani maganin miyagun ƙwayoyi daban-daban, amma acronym na iya zama rikicewa a cikin cewa wata miyagun ƙwayoyi yakan fi suna fiye da ɗaya:
R = Rituximab
C = Cyclophosphamide
H = Doxorubicin Hydrochloride (Hydroxydaunomycin)
O = Vincristine Sulfate (Oncovin)
P = Prednisone
Rituximab wani mai amfani ne wanda ya jagoranci kan antigen na CD20, wani sinadaran da ke kan al'amuran B-B da B-lymphocytes na B. Rituximab yana haifar da amsa daga masu haƙuri akan kwayoyin CD20-tabbatacce.
Cyclophosphamide an san shi a matsayin wakilin alkylating kuma yana da duka maganin ciwon daji da maganin rigakafi. A cikin hanta, cyclophosphamide ya canza zuwa metabolites wanda ke ɗaukar DNA, ya hana kwayoyin halitta daga yin kwafin DNA, da kuma farawa mutuwar cell.
Hydroxydaunomycin wani nau'i ne na maye gurbin doxorubicin, wanda aka sani da maganin kwayoyin anthracycline, kuma yana da maganin ciwon kanji.
Oncovin ko vincristine daura zuwa kananan sassa a cikin kwayoyin da ake kira microtubules kuma tsangwama tare da sel 'ikon raba.
Prednisone wani wakili mai steroid ne tare da masu amfani da anti-inflammatory, kuma yana da amfani daban-daban a magani. A wasu cututtukan ƙwayar cutar ciwon daji, ka'idar zata iya haifar da mutuwar kwayar halitta.
An yi amfani da R-CHOP a cikin lymphoma ba Hodgkin. Ana iya amfani da shi kadai, ko kuma ana iya amfani dashi tare da wasu kwayoyi ko jiyya, ko kuma a bi da sauran nau'in ciwon daji tare da lymphoma. Hakazalika, ana iya amfani da kowane mutum na R-CHOP, irin su rituximab, a cikin wasu malignancies da wasu marasa lafiya, don taimakawa wajen magance cutar.
Karin bayani kan R-CHOP
Kamar yadda ilimin ilimin lymphomas ya kara fadada, masana kimiyya suna koyo cewa bambancin sassan lymphoma guda ɗaya zasu iya amsawa daban ga tsarin da aka ba su. Gwaje-gwajen gwaji suna kallon yin amfani da sauran kayan aiki, a hade tare da R-CHOP, saboda yawancin malignancies.
R-CHOP an dauki magani na musamman ga ɗaya daga cikin nau'o'in NHL mafi yawan, yaɗa babban lymphoma B-cell, ko DLBCL . Idan ka dubi NHL a matsayin cikakke, DLBCL lambobi na kashi 25 zuwa 35 na dukan sababbin bincike a duniya a kowace shekara. R-CHOP kuma za'a iya amfani dashi a wasu lokuta na lymphoma follicular, bisa ga Jagoran 2016 daga Ƙungiyar Cibiyar Cancer ta kasa.
Yaya Sau da yawa Ana Gwada Kowane Mai Bayarwa?
Abubuwan da ke cikin dukan tsarin, ciki har da sau nawa kowanne magani ne aka ba, a kan tsawon lokaci, da kuma a cikin jerin, zai iya bambanta dangane da rashin lafiya, amsawar mai haƙuri, da likitoci ko cibiyoyi.
- Ana amfani da magunguna guda daya a matsayin mai zagaye, don haka za ku ji likitoci suyi magana game da "yawancin hawan R-CHOP" an tsara, alal misali.
- Ɗaya daga cikin yarjejeniya ta shafi aiwatar da rituximab a matsayin jiko a kan 'yan sa'o'i a ranar farko na jiyya, yayin da kwayoyi na tsarin CHOP za a iya fara ranar gobe. Za'a iya maimaita dukkanin tsari a kowace makonni uku na kimanin 6-8. Duk da haka, ƙwararrun likitoci na yau suna magana ne game da "ka'idojin CHOP-like," kuma, akwai wasu maganganu daban-daban na likitocin iya biyan wannan magungunan.
A matsayin misali na wasu ɓangarorin da ke faruwa akan R-CHOP, an kira wani abu mai suna "R - mini-CHOP" . Ƙungiyar bincike da harshen Faransa sosai - yayi nazarin tambaya game da rage yawan haɗari a cikin mutanen da ke da DLBCL shekarun 80 zuwa 95. Sunyi nufin bincika tasiri da aminci na ragewa. kashi na CHOP (doxorubicin, cyclophosphamide, vincristine, da prednisone) chemotherapy tare da tsari na al'ada na rituximab - magunguna guda daya wadanda ke dauke da kwayar cutar ta CD20 - a cikin marasa lafiya da DLBCL.
Ya zuwa yanzu, bayan shekaru biyu, sakamakon yana ƙarfafawa; Har ila yau, ya nuna muhimmancin masu haƙuri a cikin wannan rukuni.
A lokacin da aka yi amfani da tsarin ƙwayar cutar chemotherapy, ko R- "miniCHOP," inganci ya bayyana ya zama daidai a tsawon shekaru 2 zuwa daidaitattun tsari, amma tare da rageccen lokaci na hawan ƙwaƙwalwar cutar shan magani.
Hanyoyin Kasuwanci
Dukansu rituximab da CHOP sunyi tasiri, kuma cikakkun jerin abubuwan da suka shafi tasirin da ya wuce ba su da damar yin amfani da wannan labarin. Ga wasu, zaɓin tasiri masu tasiri, duk da haka:
- Kullum kuna rasa gashin kanku. Gashi a cikin girare da sauran yankuna na iya zama na bakin ciki ko fadawa. Rawan gashin gashi yana farawa bayan na farko ko na biyu na chemotherapy, kuma kusan kusan lokaci na wucin gadi cewa gashin zai fara girma bayan an gama ƙin cutar chemotherapy.
- Nuna da zubar ko jiji rashin lafiyar na kowa kuma yana iya faruwa daga nan da nan bayan jiyya ta kwana uku bayan jiyya.
- Ƙunƙwasawa zai iya fitowa saboda vincristine da sauran magunguna da za a iya ba su don tashin hankali da ciwo.
- Murmushi na iya bayyana a wani lokaci bayan jiyya, kuma wannan zai iya sa ka iya samun kamuwa da cuta a bakinka, don haka kulawa da bakin abu yana da muhimmanci.
- R-CHOP zai iya rinjayar da ikon yin ciki ko yaro yaro.
- Kuna iya kasancewa kamuwa da kamuwa da cuta a yayin kulawar CHOP, don haka kayi kokarin kaucewa haɗuwa da mutanen da ke da sanyi ko mura kuma su wanke hannuwanku akai-akai don taimakawa wajen yanke cututtukan yin kama da cutar ko kamuwa da cuta.
- R-CHOP zai iya rage adadin plalets wanda zai taimaki jini ya yi katsewa, don haka tabbatar da gaya wa likitanka idan kana da kullun ko zub da jini ba za ka iya bayyana ba.
- Prednisone yana da steroid kuma yana da tasiri mai yawa mai tasiri, ciki har da sauye-sauyen yanayi, riba, da kumburi.
> Sources:
> Offner F, Samoilova O, Osmanov E, et al. Tsarin rituximab na gaba, cyclophosphamide, doxorubicin, da kuma bortezomib (VR-CAP) ko vincristine (R-CHOP) don wadanda ba GCB DLBCL ba. Jinin jini . 2015; 126 (16): 1893-1901.
> Eyre TA, Clifford R, Roberts C, et al. Neman hannu na NCRI na biyu na binciken CHOP a hade tare da Ofatumumab a cikin shigarwa da kuma kulawa ga marasa lafiya da cutar lafiya ta Richter. BMC Kankara. 2015; 15: 52.
> Bibas M, Castillo JJ. Ilimi na yanzu game da kwayar cutar Plasmablastic Lymphoma. Madaidaita J Hematol Infect Dis. 2014; 6 (1): e2014064.